Details of the Drug Combinations

General Information of This Drug (ID: DMW73W6)

Drug Name

Andrographolide DMW73W6

Synonyms

Andrographolide; 5508-58-7; Andrographis; UNII-410105JHGR; CHEBI:65408; 410105JHGR; (S,E)-4-Hydroxy-3-(2-((1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethylidene)dihydrofuran-2(3H)-one; AK-47364; 3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one; EINECS 226-852-5; NSC 383468; 3alpha,14,15,18-tetrahydroxy-5b,9bH,10a-labda-8(20),12-dien-16-oic acid gamma-Lactone

Indication

Disease Entry	ICD 11	Status	REF
Bacillary dysentery	1A02	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Capecitabine + Andrographolide	DCFM9Q2	Capecitabine	Colorectal Neoplasms	[2]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	ClinicalTrials.gov (NCT01993472) Study of Andrographolides With or Without Capecitabine to Treat Colorectal Cancer